Lawmakers have been questioning Novo Nordisk, the company behind popular weight loss drugs Ozempic and Wegovy. The Senate wants to know why these medications are priced so much higher in the U.S. compared to other countries. For example, Americans with diabetes pay $969 per month for Ozempic, while Canadians pay just $155. The CEO of Novo Nordisk, Lars Fruergaard Jør...
Imagine a world where drugs cost differently based on where you live. That's what happened at a recent Senate hearing in Washington, D.C. Novo Nordisk's CEO, Lars Fruergaard Jorgensen, was asked some tough questions about the high prices of two important medications: Ozempic for diabetes and Wegovy for weight loss. Jorgensen blamed pharmacy benefit managers (PBMs) f...
In the United States, around 8 million individuals rely on insulin to manage their diabetes. However, the cost of insulin has skyrocketed over the past decade, leaving many patients unable to afford the life-saving medication. The Federal Trade Commission (FTC) has taken a bold step to address this issue by suing three pharmacy benefit managers (PBMs) for allegedly i...
In the world of medicine, the cost of living with diabetes is skyrocketing, and it's not just because of the drugs themselves. A recent lawsuit filed by the Federal Trade Commission (FTC) against three major pharmacy benefit managers (PBMs) sheds light on a more sinister force driving up insulin prices: the middlemen. UnitedHealth's Optum Rx, CVS Health's Caremark, a...
The American healthcare system has long been plagued by issues of affordability, but a recent Federal Trade Commission (FTC) lawsuit has brought attention to a particularly egregious example: pharmacy benefit managers (PBMs) allegedly inflating insulin prices at the expense of patients. The three largest PBMs - CVS Health's Caremark Rx, Cigna's Express Scripts, and U...